Literature DB >> 20610724

Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells.

Caroline Goujon1, Michael H Malim.   

Abstract

Type I interferon (IFN) inhibits virus replication by activating multiple antiviral mechanisms and pathways. It has long been recognized that alpha interferon (IFN-alpha) can potently block both early and late stages of HIV-1 replication. The mechanistic basis for the early block(s) to infection is unknown, as is the identity of the participating antiviral factor(s). Here, we define the effect(s) of IFN-alpha on HIV-1 infection of primary human macrophages and CD4(+) T cells, as well as several monocytic and T-cell lines. We demonstrate that IFN-alpha treatment of macrophages, THP-1 cells, and, to a lesser extent, primary CD4(+) T cells markedly inhibits infection, whereas the effects are minimal in CD4(+) T-cell lines. Virus entry is essentially unaffected by IFN-alpha, but substantial decreases (sometimes >99%) in nascent cDNA accumulation correlate closely with losses in infectivity. Interestingly, proteasome inhibitors rescue viral cDNA accumulation, revealing a link between the ubiquitin-proteasome system and IFN-alpha-induced viral restriction. We also found that diverse primate and nonprimate retroviruses were susceptible to suppression by IFN-alpha. Importantly, all the primary and immortalized cells used here are proficient at responding to IFN-alpha, as judged by the induced expression of numerous IFN-stimulated genes, including PKR and OAS1, indicating that a general deficiency in IFN-alpha responsiveness does not underlie IFN-alpha's inability to elicit an antiviral state in CD4(+) T-cell lines. Rather, we speculate that IFN-alpha fails to induce antiretroviral factors in these cells and that comparative transcriptional profiling with responsive cells, such as macrophages, invokes a strategy for identifying new host-encoded antiviral effectors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20610724      PMCID: PMC2937661          DOI: 10.1128/JVI.00854-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  126 in total

1.  Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.

Authors:  Xianghui Yu; Yunkai Yu; Bindong Liu; Kun Luo; Wei Kong; Panyong Mao; Xiao-Fang Yu
Journal:  Science       Date:  2003-10-16       Impact factor: 47.728

2.  Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro.

Authors:  D D Ho; K L Hartshorn; T R Rota; C A Andrews; J C Kaplan; R T Schooley; M S Hirsch
Journal:  Lancet       Date:  1985-03-16       Impact factor: 79.321

3.  Down-modulation of mature major histocompatibility complex class II and up-regulation of invariant chain cell surface expression are well-conserved functions of human and simian immunodeficiency virus nef alleles.

Authors:  Michael Schindler; Stephanie Würfl; Philippe Benaroch; Thomas C Greenough; Rod Daniels; Philippa Easterbrook; Matthias Brenner; Jan Münch; Frank Kirchhoff
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

4.  Further investigation of simian immunodeficiency virus Vif function in human cells.

Authors:  Nathan C Gaddis; Ann M Sheehy; K Muneer Ahmad; Chad M Swanson; Kate N Bishop; Brigitte E Beer; Preston A Marx; Feng Gao; Frederic Bibollet-Ruche; Beatrice H Hahn; Michael H Malim
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

5.  Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester.

Authors:  S Tsuchiya; Y Kobayashi; Y Goto; H Okumura; S Nakae; T Konno; K Tada
Journal:  Cancer Res       Date:  1982-04       Impact factor: 12.701

6.  Anti-human immunodeficiency virus activity of tau interferon in human macrophages: involvement of cellular factors and beta-chemokines.

Authors:  Christine Rogez; Marc Martin; Nathalie Dereuddre-Bosquet; Jacques Martal; Dominique Dormont; Pascal Clayette
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

7.  HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.

Authors:  Mariana Marin; Kristine M Rose; Susan L Kozak; David Kabat
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

8.  HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.

Authors:  Kim Stopak; Carlos de Noronha; Wes Yonemoto; Warner C Greene
Journal:  Mol Cell       Date:  2003-09       Impact factor: 17.970

9.  The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.

Authors:  Ann M Sheehy; Nathan C Gaddis; Michael H Malim
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

10.  The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.

Authors:  Matthew Stremlau; Christopher M Owens; Michel J Perron; Michael Kiessling; Patrick Autissier; Joseph Sodroski
Journal:  Nature       Date:  2004-02-26       Impact factor: 49.962

View more
  91 in total

Review 1.  Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

Authors:  Belete A Desimmie; Krista A Delviks-Frankenberrry; Ryan C Burdick; DongFei Qi; Taisuke Izumi; Vinay K Pathak
Journal:  J Mol Biol       Date:  2013-11-02       Impact factor: 5.469

2.  The cellular TAR RNA binding protein, TRBP, promotes HIV-1 replication primarily by inhibiting the activation of double-stranded RNA-dependent kinase PKR.

Authors:  Viraj R Sanghvi; Laura F Steel
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

Review 3.  Type I Interferons in NeuroHIV.

Authors:  Victoria E Thaney; Marcus Kaul
Journal:  Viral Immunol       Date:  2018-09-27       Impact factor: 2.257

4.  Virion-Associated Vpr Alleviates a Postintegration Block to HIV-1 Infection of Dendritic Cells.

Authors:  Caitlin M Miller; Hisashi Akiyama; Luis M Agosto; Ann Emery; Chelsea R Ettinger; Ronald I Swanstrom; Andrew J Henderson; Suryaram Gummuluru
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

5.  HIV-1 Env and Nef Cooperatively Contribute to Plasmacytoid Dendritic Cell Activation via CD4-Dependent Mechanisms.

Authors:  Natalia J Reszka-Blanco; Vijay Sivaraman; Liguo Zhang; Lishan Su
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

6.  Evidence for a different susceptibility of primate lentiviruses to type I interferons.

Authors:  Stéphanie Cordeil; Xuan-Nhi Nguyen; Gregory Berger; Stéphanie Durand; Michelle Ainouze; Andrea Cimarelli
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

7.  Targeting type I interferon-mediated activation restores immune function in chronic HIV infection.

Authors:  Anjie Zhen; Valerie Rezek; Cindy Youn; Brianna Lam; Nelson Chang; Jonathan Rick; Mayra Carrillo; Heather Martin; Saro Kasparian; Philip Syed; Nicholas Rice; David G Brooks; Scott G Kitchen
Journal:  J Clin Invest       Date:  2016-12-12       Impact factor: 14.808

8.  IFN-ε protects primary macrophages against HIV infection.

Authors:  Carley Tasker; Selvakumar Subbian; Pan Gao; Jennifer Couret; Carly Levine; Saleena Ghanny; Patricia Soteropoulos; Xilin Zhao; Nathaniel Landau; Wuyuan Lu; Theresa L Chang
Journal:  JCI Insight       Date:  2016-12-08

9.  Interferon-alpha mediates restriction of human immunodeficiency virus type-1 replication in primary human macrophages at an early stage of replication.

Authors:  Kelly M Cheney; Áine McKnight
Journal:  PLoS One       Date:  2010-10-20       Impact factor: 3.240

10.  Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination.

Authors:  Kieran Gillick; Darja Pollpeter; Prabhjeet Phalora; Eun-Young Kim; Steven M Wolinsky; Michael H Malim
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.